Study findings on heart bypass surgery are outlined in reports from Erasmus University
2009 AUG 3 - (NewsRx.com) -- According to recent research from Netherlands, "The The Arterial Revascularization Therapies Study (ARTS)-II trial found no differences in survival or overall adverse events between sirolimus-eluting stents (SES) and the surgical arm of ARTS-I. Nevertheless, existing data suggest that patients with disease of the proximal left anterior descending artery (LAD) may derive particular benefit from coronary artery bypass grafting (CABG)." "We therefore analysed the clinical outcome of patients in ARTS-I and ARTS-II with proximal LAD involvement. Multicentre observational study. Forty-five European academic hospitals. Patients with multivessel coronary artery disease. Patients in ARTS-II with proximal LAD disease treated with SES (289/607, 48%) were compared with 187/600 (31%) bare metal stent patients (ARTS-I BMS) and 206/605 (34%) surgical patients (ARTS-I CABG) with proximal LAD involvement from ARTS-I. Major adverse cardiac and cerebrovascular events after 3 years. The Arterial Revascularization Therapies study part 2 (ARTS-II) subgroup had better survival than both ARTS-I groups (ARTS-II 98.6% vs ARTS-I BMS 95.7%, p = 0.05 and vs ARTS-I CABG 94.7%, p = 0.01) and lower rates of the hard clinical composite endpoint of death or non-fatal myocardial infarction (ARTS-II 3.1% vs ARTS- I BMS 9.6%, p = 0.002 and vs ARTS-I CABG 9.7%, p = 0.002). Although the ARTS-I CABG patients had a lower need for repeat revascularisation than ARTS-II (5.3% vs 13.1%, p = 0.002), the overall composite adverse event rates (death, myocardial infarction, stroke or any repeat revascularisation) were not significantly different between the ARTS-I CABG and ARTS-II patients (15.0% vs 18.0%, p = 0.4)," wrote N. Kukreja and colleagues, Erasmus University. The researchers concluded: "SES are not inferior to CABG or bare metal stents for the treatment of patients with multivessel coronary disease including involvement of the proximal LAD." Kukreja and colleagues published their study in Heart (Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study par. Heart, 2009;95(13):1061-1066). For additional information, contact P.W. Serruys, Erasmus MC, Thoraxctr, Ba 583, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands. Publisher contact information for the journal Heart is: B M J Publishing Group, British Med Association House, Tavistock Square, London WC1H 9JR, England. Keywords: Netherlands, Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Angiology, Cardiology, Clinical Trial Research, Coronary Artery Bypass Graft, Coronary Artery Disease, Coronary Disease, Drugs, Heart Bypass Surgery, Heart Disease, Medical Device, Pharmaceuticals, Sirolimus, Surgery, Surgical Technology, Therapy, Treatment, Erasmus University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
